Medicenna Therapeutics Corp.
MDNA.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -9.58% | -6.98% | -18.74% | -22.54% | -22.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.22% | 10.38% | 17.14% | 15.67% | 16.25% |
| Operating Income | -2.22% | -10.38% | -17.14% | -15.67% | -16.25% |
| Income Before Tax | -40.04% | -54.58% | 52.31% | 49.25% | 51.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.04% | -54.58% | 52.31% | 49.25% | 51.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.04% | -54.58% | 52.31% | 49.25% | 51.06% |
| EBIT | -2.22% | -10.38% | -17.14% | -15.67% | -16.25% |
| EBITDA | -2.41% | -10.45% | -17.18% | -15.51% | -16.01% |
| EPS Basic | -31.72% | -41.70% | 58.51% | 55.64% | 56.69% |
| Normalized Basic EPS | -31.78% | -41.70% | 58.46% | 55.61% | 56.68% |
| EPS Diluted | -31.72% | -41.70% | 58.51% | 55.64% | 56.69% |
| Normalized Diluted EPS | -31.78% | -41.70% | 58.46% | 55.61% | 56.68% |
| Average Basic Shares Outstanding | 6.76% | 8.51% | 9.87% | 11.18% | 11.69% |
| Average Diluted Shares Outstanding | 6.76% | 8.51% | 9.87% | 11.18% | 11.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |